Dual antiplatelet therapy with aspirin and clopidogrel, a P2Y12 antagonist, is a cornerstone for treatment of patients with stroke, peripheral arterial disease and acute coronary artery disease, followed with or without percutaneous coronary intervention. In the present issue of Clinical Science, Giachini and co-workers found that clopidogrel could normalize the increased phenylephrine-induced vascular contraction and the impaired acetylcholine-induced vasodilation in mesenteric arteries from AngII (angiotensin II)-infused Sprague–Dawley rats. This might develop a new area for clopidogrel application; however, whether clopidogrel can improve arterial function in patients with hypertension or diabetes, or if clopidogrel outweighs the beneficial effect of aspirin in those patients, remains an open field for future inquiry.
Skip Nav Destination
Commentary| January 12 2010
Clopidogrel application: beyond coronary artery disease
*Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, People's Republic of China
†Department of Cardiology, The First Affiliated Hospital, Shantou Medical College, Shantou University, Shantou City, People's Republic of China
Correspondence: Dr Chunyu Zeng (email@example.com).
Search for other works by this author on:
- Views Icon Views
- Share Icon Share
Chunyu Zeng; Clopidogrel application: beyond coronary artery disease. Clin Sci (Lond) 1 April 2010; 118 (7): 459–461. doi: https://doi.org/10.1042/CS20090546
Download citation file:
Don't already have an account? Register
Get Access To This Article
Buy This Article